Researchers have successfully neutralized a genetic risk factor found in up to 80% of Alzheimer's patients. The ability to neutralize ApoE4 could help in the development of a vaccine, as well as other therapeutics, for late onset Alzheimer's.
APOEe4, a gene associated with Alzheimer's disease risk, doesn't appear to directly affect memory performance or brain activity in older adults without cognitive impairment. However, the gene does seem to influence brain regions and systems that older at-risk adults activate to support successful memory recall.
Researchers from WUSTL have identified a compound that targets APOE in mouse brains and which protects against Alzheimer's disease. The APOE4 genetic variant increases the risk of people developing Alzheimer's disease. The findings offer new possible avenues of treating the disease in humans.
APOE4 increases the inflammatory response of human microglia while reducing cellular migration. The gene also impairs the metabolic activity of the immune cells. The findings show APOE4 has a profound impact on the basic functions of microglia.
According to researchers, the APOE4 gene may interfere with memory formation.
Researchers report mice can retain their memories and ability to learn when almost all ApoE is removed from the brain but kept present in the liver to filter cholesterol.
Researchers have identified cognitive subgroups related to genetic differences in Alzheimer's patients. The findings, researchers say, could open the door for more personalized treatments of the neurodegenerative disease.
Amyloid beta pathology may be more versatile than previously thought, a new study reports.
According to researchers, children who carry the APOE4 gene and who are exposed to air pollution have higher behavior problem scores and their attention capacity was slower to develop.